Navigation Links
Aspira Scientific Introduces Xeno-free rHSA Product at World Stem Cell Summit
Date:12/5/2013

SAN FRANCISCO, Dec. 5, 2013 /PRNewswire/ -- Aspira Scientific, Inc., a research and development solutions provider for the chemical and biological sectors, today announces the official launch of its recombinant Human Serum Albumin (rHSA) product. Aspira Scientific's highly pure, cost-effective rHSA is produced from a proprietary expression technology platform, originating from rice grains (Oryza sativa) and is more than 99 percent devoid of any animal, human, or micro-organism derived components ("xeno-free"). To learn more about rHSA, visit www.aspirasci.com/rhsa.

(Logo: http://photos.prnewswire.com/prnh/20131205/AQ28432LOGO)

Produced by the innovative plant-based protein technology pioneered by Dr. Daichang Yang of Healthgen Biotechnology Co., Ltd., rHSA has the same application fields as plasma-derived Human Serum Albumin (pHSA), but offers a higher purity, more consistent, xeno-free replacement that can be manufactured to scale. Aspira Scientific's rHSA is made more cost-effectively and safely than other rHSA products, avoiding immunogenicity concerns of rHSA produced in yeast-based expression systems.

"We are proud to collaborate with our strategic manufacturing partner, Healthgen Biotechnology, to offer this ultra-pure, yet highly affordable rHSA for the research market," said Dr. John Chan, CEO, Aspira Scientific. "Our rHSA will fuel innovations in quality-demanding applications such as stem cell therapy, targeted drug delivery, and medical device coating; as well as decrease costs dramatically in high-volume applications such as cell culture media development."

Aspira Scientific's rHSA is manufactured in an ISO 9001 certified facility with rigorous quality control and superior batch-to-batch consistency. The product complies with global regulatory recommendations for non-animal derived components for pharmaceutical related research and development and is available in small-to-large scale commercial quantities.

About Aspira Scientific
Aspira Scientific empowers scientists to achieve their aspirations in chemical and biological research and development by reducing the costs of basic and applied research. The company leverages a global innovation ecosystem to offer a wide array of next-generation enabling research tools. For organizations with developmental programs and commercial intent, Aspira Scientific provides user-driven services via a "Collaborate Locally. Commercialize Globally."™ model to afford exceptional value in terms of innovation, quality and IP assurance, and cost efficiency. For more information, visit www.aspirasci.com.

MEDIA CONTACT:
Dianne Needham
Marketing Communications
dianne.needham@aspirasci.com
408.761.3738


'/>"/>
SOURCE Aspira Scientific, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Hajarian New Surgical Retractor/Aspirator May Revoultionize Surgical Retractors
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
4. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
5. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
6. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
7. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
8. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
9. Generex Augments Antigen Express Scientific Advisory Board
10. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
11. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... -- The leader in accelerated orthodontics, OrthoAccel ® ... recipient of the 2015 Townie Choice Award in the ... device that speeds up orthodontic tooth movement by as ... with treatment, AcceleDent was selected by orthodontists from across ... survey of the most reliable and reputable products ...
(Date:2/9/2016)... 9, 2016  Johnson & Johnson (NYSE: JNJ ... Healthcare Conference on Tuesday, Feb. 23, at the New ... , Vice President, Finance & Chief Financial Officer and ... the Company in a session scheduled at 10:00 a.m. ... www.investor.jnj.com . --> This webcast will ...
(Date:2/9/2016)...  The Parenteral Drug Association, Inc. (PDA), the ... sterile drug products, today announced the publication of ... With link to Comparison Spreadsheet. The document ... FDA, the EU, the Pharmaceutical Inspection Convention/Scheme and ... --> PDA,s Global Sterile Task ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... Workrite Ergonomics, who is celebrating their 25th year of business ... being an internationally recognized leader in their industry. , "We are very proud of ... of Workrite. “Workrite recognized the importance of good ergonomics before most of our ...
(Date:2/10/2016)... FLA (PRWEB) , ... February 09, 2016 , ... ... team at Clevens Face and Body Specialists are delighted to welcome a new ... ARNP joins Clevens Face and Body Specialists as a nurse practitioner performing ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... beneficiaries who are diagnosed with autism spectrum disorder (ASD). Beginning Jan. 1, 2016, ... using applied behavior analysis (ABA) is key to providing effective treatment for individuals ...
(Date:2/9/2016)... ... 09, 2016 , ... Cirracore Enterprise Cloud, today announced that ... the cloud. Cirracore provides a secure VMware® vCloud Air based cloud that ... Transformation Solutions (TSL Partners) provides a full range of services from planning, discovery, ...
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research has ... field .” , As corresponding author Dr John F. Peppin says “Terminology matters, yet ... our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete ...
Breaking Medicine News(10 mins):